Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function

Affiliations

¹ Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Location VU University Medical Center, Amsterdam, Netherlands. Electronic address: e.vanbommel@amsterdamumc.nl.
² Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada.
⁴ CardioMetabolism & Respiratory Medicine, Boehringer Ingelheim Canada Ltd./Ltée, Burlington, Ontario, Canada.
⁵ Biostatistics & Data Science, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
⁶ CardioMetabolism & Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany; Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia; Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
⁷ Department of Nephrology and Hypertension, University Medical Center, Utrecht, Netherlands.
⁸ Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Location VU University Medical Center, Amsterdam, Netherlands.

Free article

Editorial

Erik J M van Bommel et al. Kidney Int. 2020 Apr.

Free article

. 2020 Apr;97(4):631-635.

doi: 10.1016/j.kint.2019.12.021.

¹ Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Location VU University Medical Center, Amsterdam, Netherlands. Electronic address: e.vanbommel@amsterdamumc.nl.
² Department of Medicine, Division of Nephrology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
³ Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, University of Toronto, Toronto, Ontario, Canada.
⁴ CardioMetabolism & Respiratory Medicine, Boehringer Ingelheim Canada Ltd./Ltée, Burlington, Ontario, Canada.
⁵ Biostatistics & Data Science, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, Connecticut, USA.
⁶ CardioMetabolism & Respiratory Medicine, Boehringer Ingelheim International GmbH, Ingelheim, Germany; Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia; Department of Medicine, Würzburg University Clinic, Würzburg, Germany.
⁷ Department of Nephrology and Hypertension, University Medical Center, Utrecht, Netherlands.
⁸ Diabetes Center, Department of Internal Medicine, Amsterdam University Medical Centers, Location VU University Medical Center, Amsterdam, Netherlands.

No abstract available

Keywords: SGLT2 inhibition; diabetes; diabetic nephropathy; glomerular hyperfiltration.

Publication types